20 withdrawn. 20 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Withdrawn 20 |
| Phase 1 | 2 | Withdrawn 2 |
| Phase 3 | 2 | Withdrawn 2 |
Follow Schizophrenia: new trials by email Literature Review of Schizophrenia trials Research Report on Schizophrenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis Cannabidiol (CBD), Placebo - Schizophrenia Spectrum Disorders, Cannabis Use | Phase 2 | Withdrawn | University of Maryland, Baltimore | 2050-01-01 | 2021-04-19 | |
| The Sub-Sero Study Pimavanserin 34 milligrams (MG) [Nuplazid] - Schizophrenia, Psychosis | Phase 2 | Withdrawn | Bjorn H. Ebdrup | 2024-12-01 | 2024-12-09 | |
| Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia Vildagliptin 50 MG, Placebo - Schizophrenia, Dyslipidemias | Phase 2 | Withdrawn | Sadat City University | 2021-02-16 | 2025-07-14 | |
| L-arginine Study for Persistent Symptoms of Schizophrenia L-arginine, Sapropterin Dihydrochloride - Schizo Affective Disorder, Schizophrenia | Phase 2 | Withdrawn | University of Massachusetts, Worcester | 2019-09-11 | 2022-01-20 | |
| Combining rTMS With Varenicline to Prevent Smoking Lapse in Schizophrenia Active rTMS (20Hz), Sham rTMS - Tobacco Use Disorder, Schizophrenia | Phase 2 | Withdrawn | Centre for Addiction and Mental Health | 2018-07-01 | 2023-09-06 | |
| Sodium Butyrate For Improving Cognitive Function In Schizophrenia Sodium Butyrate, Placebo Oral Capsule - Schizophrenic Disorder, Cognitive Impairment | Phase 2 / Phase 3 | Withdrawn | Shanghai Mental Health Center | 2017-06-01 | 2019-01-17 | |
| Sodium Butyrate For Improving Cognitive Function In Schizophrenia Sodium Butyrate, Placebo - Schizophrenic Disorders, Cognitive Function | Phase 2 / Phase 3 | Withdrawn | Nathan Kline Institute for Psychiatric Research | 2016-04-01 | 2016-08-15 | |
| Nicotinic Receptors and Schizophrenia Risperidone plus Placebo, Risperidone plus DMXB-A - Schizophrenia | Phase 1 / Phase 2 | Withdrawn | VA Office of Research and Development | 2015-08-01 | 2017-05-30 | |
| Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia Cholecalciferol, Placebo - Schizophrenia, Schizoaffective Disorder | Phase 2 | Withdrawn | NYU Langone Health | 2015-02-01 | 2015-10-12 | |
| Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder Aripiprazole, Ingestible Event Marker (IEM) - Bipolar 1 Disorder, Schizophrenia | Phase 2 | Withdrawn | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2014-03-01 | 2015-04-28 | |
| Phosphatidylcholine Supplementation in Infants phosphatidylcholine supplementation, placebo - Schizophrenia, Diminished P50 Sensory Gating | Phase 1 / Phase 2 | Withdrawn | University of Colorado, Denver | 2013-09-01 | 2020-09-02 | |
| Transcranial Direct Current Stimulation (tDCS) as Therapeutical Strategy for Negative Symptoms in Schizophrenia Transcranial Direct Current Stimulation (tDCS) - Transcranial Direct Current Stimulation, Schizophrenia | Phase 2 | Withdrawn | University of Sao Paulo | 2012-08-01 | 2013-12-16 | |
| Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN) SCH 900435 (Org 25935), Placebo, Olanzapine - Schizophrenia | Phase 2 | Withdrawn | Merck Sharp & Dohme LLC | 2011-02-01 | 2015-12-17 | |
| Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia Org 24448, Placebo - Schizophrenia | Phase 2 | Withdrawn | University of California, Los Angeles | 2009-04-01 | 2016-02-09 | |
| A 6-Week Multicenter Trial Of Varenicline Tartrate For Cognitive Impairment In Subjects With Schizophrenia placebo, varenicline - Schizophrenia | Phase 2 | Withdrawn | Pfizer | 2009-03-01 | 2009-02-24 | |
| Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia SCA-136 50mg/day, SCA-136 150 mg/day, SCA-136 300mg/day - Schizophrenia | Phase 2 | Withdrawn | Wyeth is now a wholly owned subsidiary of Pfizer | 2008-11-01 | 2013-01-29 | |
| Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia Omega-3 fish oil capsules (including DHA), Placebo - Tardive Dyskinesia | Phase 2 | Withdrawn | Université de Montréal | 2008-02-01 | 2026-05-01 | |
| Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder modafinil - Schizophrenia | Phase 2 | Withdrawn | Manhattan Psychiatric Center | 2008-02-01 | 2020-10-14 | |
| Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia Sarcosine (N-methylglycine) - Schizophrenias, Psychoses | Phase 2 | Withdrawn | Herzog Hospital | 2006-08-01 | 2014-06-04 | |
| NRX-1074 in Early Course Schizophrenia NRX-1074, Placebo - Schizophrenia | Phase 2 | Withdrawn | NYU Langone Health | 2016-02-05 |
Psychotic Disorders (5) · Inflammation (2) · Cognitive Dysfunction (1) · Dyslipidemias (1) · Marijuana Abuse (1) · Mental Disorders (1) · Nervous System Diseases (1) · Obesity (1) · Smoking (1) · Tardive Dyskinesia (1) · Tobacco Use Disorder (1) · Treatment Adherence and Compliance (1)
Schizophrenia Spectrum and Other Psychotic Disorders (20) · Mental Disorders (19) · Pathological Conditions, Signs and Symptoms (4) · Behavior (2) · Chemically-Induced Disorders (2) · Nutritional and Metabolic Diseases (2) · Pathologic Processes (2) · Signs and Symptoms (2) · Substance-Related Disorders (2) · Body Weight (1) · Central Nervous System Diseases (1) · Cognition Disorders (1) · Dyskinesia, Drug-Induced (1) · Dyskinesias (1) · Health Behavior (1)
Butyric Acid (2) · Risperidone (2) · 1-(benzofurazan-5-ylcarbonyl)piperidine (1) · 3-(2,4-dimethoxybenzylidene)anabaseine (1) · Arginine (1) · Aripiprazole (1) · Cannabidiol (1) · Cholecalciferol (1) · Corn Oil (1) · Fish Oils (1) · Modafinil (1) · N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)aminomethylcarboxylic acid (1) · Olanzapine (1) · Phosphatidylcholines (1) · Sarcosine (1)
NYU Langone Health (2) · Bjorn H. Ebdrup (1) · Centre for Addiction and Mental Health (1) · Herzog Hospital (1) · Manhattan Psychiatric Center (1) · Merck Sharp & Dohme LLC (1) · Nathan Kline Institute for Psychiatric Research (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Pfizer (1) · Sadat City University (1) · Shanghai Mental Health Center (1) · University of California, Los Angeles (1) · University of Colorado, Denver (1) · University of Maryland, Baltimore (1) · University of Massachusetts, Worcester (1)
United States (9) · Brazil (1) · Canada (1) · China (1) · Egypt (1) · Israel (1)
Robert Freedman, MD (2) · Andre R Brunoni, PhD (1) · Bernard Lerer, M.D. (1) · Chunbo Li, M.D. (1) · Don C Goff, MD (1) · Donald C Goff, MD (1) · James D Clelland (1) · Jean-Pierre Lindenmayer, MD (1) · Pedro Shiozawa, MD (1) · Pierre J. Blanchet, MD, PhD (1) · Quirino Jr Cordeiro, PhD (1) · Robert C Smith, M.D., Ph.D (1)
PMID 22464727, PMID 29486960, PMID 32425802
2019 (1)